Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

11 Apr 2024 07:00

RNS Number : 0974K
Polar Capital Holdings PLC
11 April 2024
 

11 April 2024 Polar Capital Holdings plc

AuM Update

 

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides its regular quarterly update of its unaudited statement of Assets under Management ("AuM") for the financial year to 31 March 2024.

 

Group AuM (unaudited)

 

Polar Capital reports that as at 31 March 2024 its AuM was £21.9bn compared to £19.6bn in the previous quarter, an increase of 12%. Over the financial year there has been a 14% increase in AuM from £19.2bn at the end of March 2023. During the financial year the £2.7bn increase in AuM resulted from market movement and fund performance of £4.3bn, offset by net redemptions of £1.6bn.

 

AuM movement in twelve months to 31 March 2024

Open ended

funds

Investment

Trusts

Segregated mandates

Total

AuM at 1 April 2023

£14,281m

£3,910m

£1,029m

£19,220m

Net flows

£(1,224)m

£(154)m

£(235)m

£(1,613)m

Fund closures1

£(7)m

-

£(43)m

£(50)m

Market movement

and performance

£2,938m

£1,332m

£65m

£4,335m

Total AuM at 31 March 2024

£15,988m

£5,088m

£816m

£21,892m

1 Return of funds to investors on closure of the Melchior European Absolute Return fund (Q1) and related segregated mandate (Q2).

 

Gavin Rochussen, Chief Executive, commented:

 

"Given the backdrop of challenging conditions for the asset management industry, and following a number of quarters of net outflows, it is pleasing to be able to report net inflows of £56m during the final quarter of the financial year ended 31 March 2024.

 

"With interest rates having potentially peaked, global equity markets continued to rise during the quarter and as a result total AuM in the quarter increased by £2.3bn from £19.6bn to £21.9bn, a 12% increase.

 

"A combination of net outflows and a fund closure were offset by market and fund performance resulting in our AuM at the end of the financial year increasing by 14% to £21.9bn from £19.2bn at the end of March 2023.

 

"Net flows during March 2024 have been particularly pleasing with six of our strategies benefitting from net inflows with an overall total of £228m during the month. While the outlook for fund flows remains uncertain, positive momentum has continued into April 2024.

 

"There have been inflows into the Global Absolute Return, Emerging Market Stars, Asian Stars, Biotechnology, Global Insurance, Japan Value, Global Technology, Artificial Intelligence and UK Value funds, with combined net inflows of £332m across these funds during the month of March 2024.

 

"During the quarter, the open-ended Technology funds saw net inflows of £327m compared to £136m of net outflows in the previous quarter, with £212m of net inflows during the month of March 2024.

 

"During the quarter we announced that Dan Boston will be joining Polar Capital in September 2024 to lead a new International Small and Mid-Cap Equities investment team and launch a new mutual fund that will complement our existing offering in the US market. Dan brings nearly 20 years of experience in international small and mid-cap company investing, and most recently he worked at Brown Capital Management in Baltimore, Maryland, where he led the International Small Company strategy, which managed $3.5bn across a 5-star Morningstar-rated mutual fund and various managed accounts. He joined Brown Capital Management in 2019 after serving as a Partner and Senior Portfolio Manager at Baird, overseeing its International Small Cap and Global and International Large Cap strategies.

 

"Whilst global financial markets remain exposed to several headwinds, the potential of interest rates peaking and central banks beginning to consider the possibility of rate cuts bodes well for equities in general and investors will, we believe, continue to seek additional exposure to the asset class. Our pipeline of client interest remains strong, and we have the capacity to meet investor demand for our active specialist fund strategies.

 

"We remain confident that with our diverse range of differentiated active specialist fund strategies we are well-positioned to perform for our clients and shareholders over the long term."

 

Polar Capital aims to announce its results for the financial year to 31 March 2024 on 27 June 2024.

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

Samir Ayub (Finance Director)

 

+44 (0)20 7227 2700

Numis Securities Limited - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

Stephen Westgate

 

+44 (0)20 7260 1000

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

John Welch

Sam Milford

 

 

 

+44 (0)20 3597 8680

Camarco

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

 

+44 (0)20 3757 4995

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAKLEFAFLEFA
Date   Source Headline
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application
28th Jun 20185:55 pmRNSAnnual Financial Report
25th Jun 20187:00 amRNSGroup Audited Results for year ended 31 March 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.